Matthew Vander Heiden MD, PhD

Matthew Vander Heiden is the director of the Koch Institute at MIT, the Lester Wolfe (1919) Professor of Molecular Biology, and a member of the Broad Institute. He is a practicing oncologist and instructor in medicine at Dana-Farber Cancer Institute/Harvard Medical School. He earned his doctoral and medical degrees from the University of Chicago, where he worked in the laboratory of Craig Thompson. Vander Heiden then completed a residency in internal medicine at Boston's Brigham & Women's Hospital and a hematology-oncology fellowship at Dana-Farber Cancer Institute/Massachusetts General Hospital.

He was a postdoctoral fellow in the laboratory of Lewis Cantley at Harvard Medical School before joining the MIT faculty in 2010. Vander Heiden serves on the scientific advisory board of Yale Cancer Center, Salk Cancer Center, Wistar Cancer Center, Jackson Labs, MGH, CSI-Singapore, IFOM Milan, Agios Pharmaceuticals, iTeos Therapeutics, Pretzel Therapeutics, Lime Therapeutics, Sage Therapeutics, and Auron Therapeutics, of which he is also an academic founder. He is part of the investment advisory board for DROIA Venture Fund and MPM Capital.